Cromoglicic acid

Generic Medicine Info
Indications and Dosage
Asthma prophylaxis
Adult: 20 mg four times daily as dry powder/nebulised soln or 10 mg four times daily as aerosol, increased to 6-8 times daily if necessary, reduced to 5 mg four times daily once asthma has been stabilised. Additional doses may be taken before exercise.

Allergic rhinitis
Adult: 2.5 or 5 mg of a 2% or 4% soln is admin as drops or spray into each nostril 4 times daily.

Allergic conjunctivitis
Adult: Instill 2 drops of a 4% soln 4-6 times daily or apply a 4% oint bid-tid.

Food allergy, Mastocytosis
Adult: 200 mg four times daily. May double the dose if effect is not satisfactory within 2-3 wk. Max: 40 mg/kg/day.
Child: 100 mg four times daily. May double the dose if effect is not satisfactory within 2-3 weeks.
Renal Impairment
Dosage adjustment may be needed.
Hepatic Impairment
Dosage adjustment may be needed.
Special Precautions
Lactation, cardiac arrhythmias, hepatic or renal dysfunction.
Adverse Reactions
Nausea, headache, dizziness, unpleasant taste, joint pain and swelling, skin rashes, aggravation of asthma, pulmonary infiltrates with eosinophilia, urticaria. Bronchospasm, wheezing, cough, nasal congestion and throat irritation following inhalation of dry powder. Intranasal use: Transient irritation of nasal mucosa. Sneezing and epistaxis (occasional). Eye drops: Transient burning and stinging.
Description: Cromoglycic acid inhibits degranulation of mast cells and therefore suppresses the release of histamine, leukotrienes and slow-reacting substance of anaphylaxis.
Absorption: Oral: Poorly absorbed from the GIT with only 1% bioavailability. Inhalation: 8-10% of a dose of fine powd is deposited and rapidly absorbed from the lungs. Intranasal: < 7% of the dose is absorbed. Ophthalmic: 0.03% is absorbed.
Store at 25°C.
MIMS Class
Antihistamines & Antiallergics / Nasal Decongestants & Other Nasal Preparations / Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories
Disclaimer: This information is independently developed by MIMS based on Cromoglicic acid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
  • Cromabak
  • Vividrin
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in